The court intends to strike down the tariffs by mid-October, pending a Supreme Court review of the ruling.
Appellate court rules Trump’s global tariffs illegal, but delays action Read More »
The French giant is gaining access to darovasertib, a small molecule protein kinase C inhibitor already in Phase II/III trials, with rights for the whole world besides the U.S.
Servier Commits up to $530M Into Eye Cancer Deal With IDEAYA Read More »
Vertex Pharmaceuticals commits $45 million upfront to leverage Enlaza Therapeutics’ War-Lock platform to create drug conjugates and T cell engagers for autoimmune diseases and gentler conditioning for sickle cell/beta thalassemia gene-editing therapy Casgevy.
Vertex, Enlaza Declare War on Autoimmune Disease in Potential $2B+ Pact Read More »
Edimakor × Veo3: La Mejor Herramienta Transformando tus Textos en Videos Profesionales 2025 Una posibilidad al alcance de tus manos, es una gran oportunidad… La inteligencia artificial llegó para servirnos en multiplicidad de aspectos, siendo los m&aac …
Cómo Crear Videos con Texto usando IA: Edimakor + Veo 3 2025 Read More »
The OMass partnership will boost Roche’s strategy in inflammatory bowel diseases, currently led by afimkibart, an anti-TL1A therapy the pharma obtained from its $7.1 billion acquisition of Telavant in 2023.
Roche Makes Preclinical IBD Play in $420M+ OMass Pact Read More »
Lilly is pushing forward with one more Phase II study of naperiglipron, which uses the same scaffold as Pfizer’s failed obesity drugs danuglipron and lotiglipron.
Lilly Ends Two Mid-Stage Trials for Second Obesity Pill Read More »
While the approval of Leqembi Iqlik bodes well for Biogen and Eisai’s planned application for a subcutaneous induction regimen next year, its financial impact remains “uncertain,” as potentially higher revenues from the injection could be offset by steeper costs of production, according to Jefferies.
Biogen, Eisai Win FDA Nod for Subcutaneous Maintenance Leqembi Read More »
Novo Nordisk’s Wegovy has been on a winning streak as of late, with a metabolic dysfunction-associated steatohepatitis approval last month and prime position in the oral obesity race.
Novo’s Wegovy Cuts Cardio Risk by 57% Versus Tirzepatide Read More »
Más allá de las herramientas aisladas, la nueva era de la gestión se basa en tener una réplica digital y en tiempo real de todo tu negocio para tomar decisiones basadas en datos, no en intuición. En el complejo ecosistema de las pequeñas y …
La leucemia linfocítica crónica es la forma más común de leucemia en el mundo occidental. Se trata de una enfermedad altamente heterogénea, en la que algunos pacientes experimentan una progresión rápida y requieren tratamiento, mientras que otros pued …
Nuevo modo de predecir la evolución clínica de la gente con leucemia Read More »
